NCT03617484
Withdrawn
Phase 2
Phase II Study Evaluating the Effect of Adding Bortezomib to Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma
Overview
- Phase
- Phase 2
- Intervention
- Bortezomib
- Conditions
- Mantle Cell Lymphoma
- Sponsor
- University of Michigan Rogel Cancer Center
- Locations
- 1
- Primary Endpoint
- The proportion of participants that respond to treatment at 6 months
- Status
- Withdrawn
- Last Updated
- 5 years ago
Overview
Brief Summary
This is a phase II study to evaluate the efficacy of ibrutinib in combination with bortezomib in in MCL (mantle cell lymphoma) patients who relapsed on single agent ibrutinib.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Men and women ≥ 18 years of age
- •Diagnosis of mantle cell lymphoma established by histologic assessment by a hemato-pathologist with additional assessment of the histologic diagnosis by immunohistochemistry or flow cytometry.
- •Patients with history of MCL that has relapsed (documented disease progression after previously responding) to therapy (CR/PR) on single agent ibrutinib (treated for at least 6 months) as the last treatment prior to enrollment.
- •Adequate liver, renal and bone marrow function
- •Adequate coagulation (unless abnormalities are unrelated to coagulopathy or bleeding disorder)
- •Female subjects of childbearing potential must have a negative urine/serum pregnancy test upon study entry. Women as well are not advised to breastfeed during treatment with bortezomib and for 2 months after treatment.
- •Male and female subjects of reproductive potential must agree to use both a highly effective method of birth control and barrier method during the period of therapy and for 30 days after the last dose of study drug for females and 90 days for males.
- •Eastern Cooperative Oncology Group (ECOG) performance status of \<2 (Eastern Cooperative Oncology Group scoring system used to quantify general well-being and activities of daily life; scores range from 0 to 5 where 0 represents perfect health and 5 represents death.)
Exclusion Criteria
- •Concurrent diagnosis of another malignancy unless treated with curative intent more than 2 years from study start (basal/squamous cell carcinoma of the skin is not an exclusion).
- •Previous treatment with bortezomib.
- •Patients who are eligible for autologous stem cell transplant are excluded unless they refuse this procedure.
- •History of allogeneic stem cell transplant.
- •Other exclusions (certain concurrent conditions) per protocol
Arms & Interventions
Bortezomib + Ibrutinib
Ibrutinib will be administered orally at a dose of 560 mg daily for each 21 day cycle. Bortezomib will be administered subcutaneously at a dose of 1.3 mg/m\^2 on days 1, 4, 8, and 11 of each 21-day cycle.
Intervention: Bortezomib
Bortezomib + Ibrutinib
Ibrutinib will be administered orally at a dose of 560 mg daily for each 21 day cycle. Bortezomib will be administered subcutaneously at a dose of 1.3 mg/m\^2 on days 1, 4, 8, and 11 of each 21-day cycle.
Intervention: Ibrutinib
Outcomes
Primary Outcomes
The proportion of participants that respond to treatment at 6 months
Time Frame: 6 Months
The primary endpoint is overall response rate (ORR). Participants will be evaluated for response based on the Lugano criteria.
Secondary Outcomes
- Rate of complete response(Up to 10 Years)
- Time to progression(Up to 10 Years)
- Overall survival time(Up to 10 Years)
- Progression free survival time(Up to 10 Years)
- Best overall response(Up to 10 Years)
Study Sites (1)
Loading locations...
Similar Trials
Withdrawn
Phase 2
Ibrutinib With or Without Bortezomib and Dexamethasone in Treating Patients With Relapsed or Refractory Immunoglobulin Light Chain AmyloidosisAmyloidosisImmunoglobulin Light Chain DepositionNCT03130348Mayo Clinic
Unknown
Phase 2
Bortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer PatientsOvarian Neoplasm EpithelialHigh Grade Serous CarcinomaNCT03509246Seoul National University Hospital44
Active, not recruiting
Phase 1
A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaChronic Lymphocytic LeukemiaNCT02537613Dana-Farber Cancer Institute54
Completed
Phase 1
Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid LeukemiaAcute Myeloid LeukemiaAdult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Acute Myelomonocytic Leukemia (M4)Adult Erythroleukemia (M6a)Adult Pure Erythroid Leukemia (M6b)Untreated Adult Acute Myeloid LeukemiaNCT00742625National Cancer Institute (NCI)95
Completed
Phase 1
Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refractory Multiple MyelomaMultiple MyelomaNCT00972712Emory University12